Nikolaizik W H, Crameri R, Blaser K, Schöni M H
Alpine Children's Hospital, Davos, Switzerland.
Int Arch Allergy Immunol. 1996 Dec;111(4):403-8. doi: 10.1159/000237399.
We evaluated the diagnostic value of recombinant Aspergillus fumigatus allergen I/a (rAsp f I/a) for skin testing in cystic fibrosis (CF) patients with allergic bronchopulmonary aspergillosis (ABPA), allergy to A. fumigatus and in CF controls not allergic to A. fumigatus. Skin prick test reactions to rAsp f I/a were 8.5-fold stronger in A.-fumigatus-allergic and 3.3-fold stronger in ABPA patients compared to the CF controls. Three out of 6 well-characterized ABPA patients had positive skin prick test reactions to rAsp f I/a; the same number reacted to crude A. fumigatus extracts. The skin prick test results to rAsp f I/a were significantly correlated with those to crude and commercial preparations. According to these results, rAsp f I/a represents a defined allergen that provides the possibility to perform skin prick tests in CF patients in a highly standardized way. In future, a larger panel of recombinant allergens might also pick up those CF patients with ABPA and allergy to A. fumigatus who did not react to this single allergen.
我们评估了重组烟曲霉变应原I/a（rAsp f I/a）对囊性纤维化（CF）合并变应性支气管肺曲霉病（ABPA）患者、对烟曲霉过敏的CF患者以及对烟曲霉不过敏的CF对照者进行皮肤试验的诊断价值。与CF对照者相比，对rAsp f I/a的皮肤点刺试验反应在烟曲霉过敏患者中强8.5倍，在ABPA患者中强3.3倍。6例特征明确的ABPA患者中有3例对rAsp f I/a的皮肤点刺试验反应呈阳性；对粗制烟曲霉提取物有反应的患者数量相同。rAsp f I/a的皮肤点刺试验结果与粗制和商业制剂的结果显著相关。根据这些结果，rAsp f I/a是一种明确的变应原，它使得以高度标准化的方式对CF患者进行皮肤点刺试验成为可能。未来，更多的重组变应原可能还会检测出那些对这种单一变应原无反应的合并ABPA且对烟曲霉过敏的CF患者。
